The prognosis of patients with previously treated tuberculosis (TB) was suggested to be dependent on whether the initial treatment was in compliance with the established guidelines. The aim of this retrospective multicenter study was to determine the proportion of new TB patients who received standard doses of rifampicin in multiple provinces of China, and the relationship between low doses of rifampicin and frequency of rifampicin-resistance as well as treatment outcomes. A total of 713 new TB patients were treated with either once-daily dose of bulk anti-TB drugs (group I) or every other day combination blister packs of anti-TB drugs containing rifampicin (group II) at more than 30 TB treatment centers/hospitals in China. Treatment history, therapeutic doses of rifampicin, and information about patients were extracted from their medical records and analyzed, and rifampicin-resistance of isolates collected from patients following the treatment as well as treatment outcomes were compared between two treatment groups. Among 522 patients in treatment group I, 154 (29.5%) received standard and 363 (69.5%) received low doses of rifampicin; 238 (45.6%) isolates were rifampicin-resistant, and 243 (46.6%) were successfully treated. Among 191 patients in treatment group II, 175 (91.6%) received standard and 15 (7.9%) received low doses of rifampicin; 72 (37.7%) isolates were rifampicin-resistant, and 105 (55%) were successfully treated. When patients who received low doses of rifampicin were compared to others within the same treatment group, increased rates for rifampicin-resistance and treatment failure were observed. Results from this study showed that most new TB patients in treatment group I (69.5%) received low doses of rifampicin, and their treatment outcomes were worse than those in treatment group II, indicating that low doses of rifampicin used for the initial treatment of new TB patients were correlated to increased frequency of rifampicin-resistance and poorer treatment outcomes.
Tuberculosis (TB) is one of the leading infectious diseases in the world. An estimated 9.0 million people developed TB in 2013 and 0.48 million of them were multidrug-resistant (MDR)-TB [
Previous studies suggested that the prognosis of patients with previously treated pulmonary TB was depen- dent on whether or not the initial treatment of new cases was in compliance with the established guidelines [
In this retrospective multicenter study, we aimed to determine the proportion of new TB patients who re- ceived standard doses of rifampicin in multiple provinces of China and the relationship between low doses of rifampicin used for the initial treatment of new TB patients and frequency of rifampicin-resistance as well as treatment outcomes.
The Medical Ethics Committee at Beijing Chest Hospital approved this study before the study began, and written informed consent forms were signed by participants for their clinical records to be used in this study. Patients diagnosed as sputum smear positive (acid-fast bacilli staining) and culture positive pulmonary TB were treated previously with bulk drugs or combination blister packs of anti-TB drugs at more than 30 TB prevention and treatment centers/hospitals in multiple provinces of China between July 2009 and July 2011. The selection criteria of patients included those who were diagnosed as active pulmonary TB and treated previously. Patients were ineligible for this retrospective multicenter study if they had non-TB mycobacterial lung diseases, combined extrapulmonary TB, combined severe diseases in heart, liver and kidney, malnutrition, human immunodeficiency virus (HIV), diabetes complications, pneumoconiosis, blood disorders, digestive diseases, etc. Patients were also excluded if their records were incomplete.
For the initial treatment of new TB patients, physicians at specialized TB hospitals usually prescribe once- daily doses of bulk anti-TB drugs including rifampicin (300 - 750 mg) individually to patients according to their different circumstances (group I). Whereas, health care providers at TB prevention and treatment centers (or local sites of the Chinese CDC) generally use combination blister packs of anti-TB drugs containing 600 mg of rifampicin as the intermittent therapy every other day for new TB patients (group II). Patients in both groups received an initial phase of two-month oral regimens of four first-line anti-TB drugs followed by a continuation phase of about four months using isoniazid and rifampicin.
Staff involved in collection of data from patients, culture of sputum samples collected from TB patients in two treatment groups following the treatment on Löwenstein-Jensen (L-J) solid media (purchased from the same supplier), drug susceptibility testing (DST) on collected isolates with M. tuberculosis strain H37Rv as the control, and submission of data online at each center were trained by experts using the same training materials and standard operation protocols.
A standard web-based questionnaire was created specifically for this study to extract a variety of data about TB patients who were treated between July 2009 and July 2011 in two treatment groups at more than 30 TB prevention and treatment centers/hospitals in multiple provinces of China. The data including previous treatment history, therapeutic doses of rifampicin used in the initial treatment, DST results against rifampicin for isolates collected from patients following the treatment, treatment outcomes, plus gender, age, and body weight of patients at the time of the initial treatment were extracted from patients’ medical records at each participating center or hospital. After collection at each participating center, data were uploaded immediately to the main server located in Beijing Chest Hospital. Completed reports were reviewed and verified by the project manager, and selected for this study if they met the inclusion criteria.
According to the established guidelines [
A total of 713 patients with previously treated smear positive pulmonary M. tuberculosis were selected for this retrospective multicentre study (
To determine whether low doses of rifampicin used in the initial treatment of new TB patients were correlated to increased frequency of rifampicin-resistance and poorer treatment outcomes in previously treated TB patients, we compared the number of patients who were treated with low doses of rifampicin, the frequency of rifampicin-resistance and treatment outcomes between two treatment groups following the treatment. As indicated in
Results from drug susceptibility testing (DST) conducted on M.tb cultures collected following the treatment showed that 45.6% of clinical isolates (238/522) collected from TB patients in treatment group I and 37.7% of clinical isolates (72/191) collected from TB patients in treatment group II were resistant to rifampicin, and the difference between two groups was statistically significant (P < 0.0304). We also observed that rifampicin-
| Characteristics | Patient no. (%) | Group Ia (%) | Group IIb (%) |
|---|---|---|---|
| Gender | |||
| Male | 527 (73.9) | 382 (73.2) | 145 (75.9) |
| Female | 186 (26.1) | 140 (26.8) | 46 (24.1) |
| Age group (years) | |||
| 12 - 19 | 20 (2.8) | 17 (3.3) | 3 (1.6) |
| 20 - 29 | 139 (19.5) | 100 (19.2) | 39 (20.4) |
| 30 - 39 | 161 (22.6) | 117 (22.4) | 44 (23.0) |
| 40 - 49 | 176 (24.7) | 132 (25.3) | 44 (23.0) |
| 50 - 59 | 139 (19.5) | 96 (18.4) | 43 (22.5) |
| 60 - 69 | 58 (8.1) | 45 (8.6) | 13 (6.8) |
| >70 | 20 (2.8) | 15 (2.9) | 5 (2.6) |
| Weight (kg) | |||
| <50 | 164 (23.0) | 110 (21.1) | 54 (28.3) |
| 50 - 70 | 475 (66.6) | 347 (66.5) | 128 (67.0) |
| >70 | 74 (10.4) | 65 (12.5) | 9 (4.7) |
| Total | 713 (100) | 522 (73.2) | 191 (26.8) |
aGroup I, rifampicin once daily therapy doses ranging from 300 mg to 750 mg; bGroup II, intermittent therapy every other day with combination blister packs of anti-TB drugs containing 600 mg of rifampicin.
| Patient no. | Number (%) of patients treated with | |||||||
|---|---|---|---|---|---|---|---|---|
| Standard doses | Low doses | High doses | ||||||
| Gender | ||||||||
| Male | 382 | 94 (24.6) | 285 (74.6) | 3 (0.8) | ||||
| Female | 140 | 60 (42.9) | 78 (55.7) | 2 (1.4) | ||||
| Age (years) | ||||||||
| 12 - 19 | 17 | 10 (58.8) | 7 (41.2) | 0 (0) | ||||
| 20 - 29 | 100 | 28 (28.0) | 71 (71.0) | 1 (1.0) | ||||
| 30 - 39 | 117 | 33 (28.2) | 82 (70.1) | 2 (1.7) | ||||
| 40 - 49 | 132 | 40 (30.3) | 91 (68.9) | 1 (0.8) | ||||
| 50 - 59 | 96 | 28 (29.2) | 67 (69.8) | 1 (1.0) | ||||
| 60 - 69 | 45 | 9 (20.0) | 36 (80.0) | 0 (0) | ||||
| ≥70 | 15 | 6 (40.0) | 9 (60.0) | 0 (0) | ||||
| Weight (kg) | ||||||||
| <50 | 110 | 100 (90.9) | 6 (5.5) | 4 (3.6) | ||||
| 50 - 70 | 347 | 42 (12.1) | 304 (87.6) | 1 (0.3) | ||||
| >70 | 65 | 12 (18.5) | 53 (81.5) | 0 (0) | ||||
| Total | 522 | 154 (29.5) | 363 (69.5) | 5 (1.0) | ||||
| Patient no. | Number (%) of patients treated with | |||||||
|---|---|---|---|---|---|---|---|---|
| Standard doses | Low doses | High doses | ||||||
| Gender | ||||||||
| Male | 145 | 133 (91.7) | 11 (7.6) | 1 (0.7) | ||||
| Female | 46 | 42 (91.3) | 4 (8.7) | 0 (0) | ||||
| Age (years) | ||||||||
| 12 - 19 | 3 | 3 (100.0) | 0 (0) | 0 (0) | ||||
| 20 - 29 | 39 | 35 (89.7) | 3 (7.7) | 1 (2.6) | ||||
| 30 - 39 | 44 | 40 (90.9) | 4 (9.1) | 0 (0) | ||||
| 40 - 49 | 44 | 40 (90.9) | 4 (9.1) | 0 (0) | ||||
| 50 - 59 | 43 | 42 (97.7) | 1 (2.3) | 0 (0) | ||||
| 60 - 69 | 13 | 11 (84.6) | 2 (15.4) | 0 (0) | ||||
| ≥70 | 5 | 4 (80.0) | 1 (20.0) | 0 (0) | ||||
| Weight (kg) | ||||||||
| <50 | 54 | 50 (92.6) | 4 (7.4) | 0 (0) | ||||
| 50 - 70 | 128 | 118 (92.2) | 9 (7.0) | 1 (0.8) | ||||
| >70 | 9 | 7 (77.8) | 2 (22.2) | 0 (0) | ||||
| Total | 191 | 175 (91.6) | 15 (7.9 ) | 1 (0.5) | ||||
| Variables | Patient no. (%) | ||
|---|---|---|---|
| Group Ia (N = 522) | Group IIb (N = 191) | P value | |
| Low doses | 363 (69.5) | 15 (7.9) | <0.0001 |
| Standard doses | 154 (29.5) | 175 (91.6) | <0.0001 |
| High doses | 5 (1.0) | 1 (0.5) | |
| Rifampicin-resistance | 238 (45.6) | 72 (37.7) | 0.0304 |
| Successful treatment outcomes | 243 (46.6) | 105 (55.0) | 0.0093 |
aGroup I, rifampicin once daily therapy doses ranging from 300 mg to 750 mg; bGroup II, intermittent therapy every other day with combination blister packs of anti-TB drugs containing 600 mg of rifampicin.
resistance rate of isolates collected from patients who received low doses of rifampicin (46.2% in group I and 40% in group II) was higher than those collected from patients who received standard and high doses of rifampicin (40.7% in group I and 37.5% in group II) within the same treatment group. When treatment outcomes were compared between two groups, we found that 46.6% of patients (243/522) in treatment group I and 55.0% of patients (105/191) in treatment group II were successfully treated, and the difference was statistically significant (P < 0.0093). The rate of successful treatment for patients in two groups whose isolates were rifampicin-resis- tance (24.4% in group I and 34.7% in group II) was lower than those whose isolates were rifampicin-susceptible within the same treatment group (65.1% in group I and 67.2% in group II). Results from this study indicated that the initial treatment for new TB patients with every other day combination blister packs of anti-TB drugs con- taining rifampicin (group II) was better than those with daily dose of bulk anti-TB drugs including rifampicin (group I) in terms of frequency of rifampicin-resistance and treatment outcomes.
Results from this retrospective multicenter study confirmed that 91.6% of new TB patients treated at many TB Prevention and Treatment centers (group II), and 29.5% of those treated at specialized TB hospitals (group I) in China did receive standard doses of rifampicin. Due to less human factors were involved in the use of combination blister packs, most of TB patients in treatment group II received standard doses of rifampicin. However, the use of combination blister packs has its own drawbacks, for example, if patients forget to take the medicines, the time intervals between treatments will be extended which can affect the treatment efficacy. Fixed-dose combination (FDC) tablets containing a variety of anti-TB drugs in the proper dosages were recommended by both WHO and the International Union against Tuberculosis and Lung Diseases (IUATLD) as a means to simplify administration of drugs by reducing the number of pills patients take and decreasing the risks of incorrect prescriptions and development of drug resistance [
Our results also show that 69.5% of new TB patients treated at specialized TB hospitals (group I) and 7.9% of those treated at TB prevention and treatment centers (group II) in multiple provinces of China received low doses of rifampicin. As one of the most important anti-TB drugs, rifampicin must be administered adequately in accordance with the established guidelines [
dence is very low, and death if patients are not rescued immediately or it happens to elderly patients [
Comparison results show that the percentage of rifampicin-resistance for clinical isolates collected from TB patients in treatment group I (45.6%) was significantly higher than those in treatment group II (37.7%), and the rate of successful treatment for patients in treatment group I (46.6%) was significantly lower than those in treatment group II (55%). Our results indicate that low doses of rifampicin used in the initial treatment of patients with TB are indeed correlated to increased frequency of rifampicin-resistance and poorer treatment outcomes, and support the idea of using higher doses of rifampicin for new TB patients to shorten the treatment duration, to reduce rifampicin-resistance, and to improve treatment outcomes.
Because this retrospective multicenter study was not a double-blind placebo-controlled clinical trial, it had some potential limitations. In addition to the difference in doses of rifampicin received by TB patients in two treatment groups, other variable factors such as administering methods for rifampicin and doses of three other first-line anti-TB drugs may also affect the frequency of rifampicin-resistance and treatment outcomes. To over- come these potential limitations, confirm the conclusions of the current study, and prove the potential benefits and unanticipated risks of using higher doses of rifampicin, multicenter randomized double-blind placebo-con- trolled clinical studies with more new patients with pulmonary TB in each group will need to be properly designed and conducted.
Currently, one clinical trial is planning to recruit 180 participants with active, infectious, drug-susceptible TB in Peru to evaluate the potential of higher doses of rifampicin (15 mg/kg/day and 20 mg/kg/day) to shorten treatment for tuberculosis without causing more adverse events (http://clinicaltrials.gov/show/NCT01408914). Results from a recently published study using a murine model indicated that even the standard rifampicin dosage (10 mg/kg/day) was too low, and a rifampicin dosage of 80 mg/kg/day significantly reduced therapy duration without adverse effects, which suggested that much higher doses of rifampicin might lead to a more rapid treatment response and the shortened treatment course [
Results from our study indicate that low doses of rifampicin used for the initial treatment of new pulmonary TB patients are correlated to increased frequency of rifampicin-resistance and poorer outcomes, and the difference between two treatment groups is statistically significant. Our results also provide clinical evidence to support the idea of using higher doses of rifampicin to shorten the treatment duration, reduce the frequency of rifampicin- resistance, and improve the treatment outcomes for patients with pulmonary TB.
The authors would like to thank all the participants of this study and are greatly appreciated the supports from the following institutions, hospitals, and individuals: Beijing Chest Hospital/Beijing Institute of Tuberculosis and Thoracic Tumor (X Huang), Affiliated Hospital of Zunyi Medical College (JY Zhang), Shenyang Chest Hospital (X Liang), The First Affiliated Hospital of Xinxiang Medical College (H Shang), Heilongjiang Institute of Tuberculosis Control (X Yan), Harbin Chest Hospital (B Ji), the Jingmen Third Hospital of Infectious Diseases (S Chen), Center for Disease Control, Beijing (X Wu), Beijing Geriatric Hospital (W Cao), The Fourth Hospital of Tangshan (P Zhang), the Third Qinhuangdao Hospital (X Leng), Xuzhou Hospital of Infectious Diseases (HQ Zhang), Department of Pneumonoconiosis and Tuberculosis, Beijing Jingmei Group General Hospital (D Chen), The 309th Hospital of Chinese People’s Liberation Army (JQ Liang), Anhui Provincial Chest Hospital (GW Chen), Hunan Provincial Tuberculosis Hospital (KY Yang), Infectious Disease Prevention and Treatment Hospital of Heilongjiang Province (YQ Liu), Affiliated Shanghai Pulmonary Hospital of Tongji University (SJ Tang), Shandong Provincial Chest Hospital (LH Qiu), Tuberculosis Prevention and Treatment Hospital of Shanxi Province (GQ Niu), The 3rd People’s Hospital of Shenzhen City (WY Yu), Shanghai Municipal Center for Disease Prevention and Control (XQ Li), Guangzhou Chest Hospital (SY Tan), Hebei Provincial Center for Disease Prevention and Control (LY Zhang), Center for Disease Prevention and Control of Guangxi Zhuang Autonomous Region (FY Liu), Tuberculosis Prevention and Treatment Hospital of Chongqing City (DY Hu), and Yunnan Provincial Center for Disease Prevention and Control (YL Zhang). This study was funded by the “Eleventh Five-Year” Major National Research Project on treatment strategies for previously treated TB (2008ZX10003-015), Comprehensive Treatment of MDR-TB (2008ZX10003-014), and Clinical Occurrence and Early Warning Model for Drug-Resistant TB (2008ZX10003-008). Study sponsors played no role in study design; in the writing of the report; and in the decision to submit the paper for publication.
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. All authors except HZ declare no conflicts of interest. HZ has shares in Z-BioMed, which is involved in infectious disease research.
CDC: Centers for Disease Control and Prevention
DST: Drug Susceptibility Testing
FDC: Fixed-Dose Combination
HIV: Human Immunodeficiency Virus
IUATLD: International Union against Tuberculosis and Lung Diseases
L-J: Löwenstein-Jensen
MDR: Multidrug-Resistant
Mtb: Mycobacterium Tuberculosis
TB: Tuberculosis